Fairfield Bush & CO. Maintains Holdings in Biogen Inc. (BIIB)

Fairfield Bush & CO. continued to hold its position in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the biotechnology company’s stock at the end of the second quarter. Fairfield Bush & CO.’s holdings in Biogen were worth $2,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pathstone Family Office LLC acquired a new position in shares of Biogen in the 1st quarter valued at $102,000. Prentiss Smith & Co. Inc. lifted its stake in shares of Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 50 shares during the period. Independent Portfolio Consultants Inc. lifted its stake in shares of Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 219 shares during the period. Winfield Associates Inc. lifted its stake in shares of Biogen by 16.8% in the 1st quarter. Winfield Associates Inc. now owns 467 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 67 shares during the period. Finally, Carroll Financial Associates Inc. lifted its stake in shares of Biogen by 1.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 6 shares during the period. Hedge funds and other institutional investors own 87.65% of the company’s stock.

Biogen Inc. (NASDAQ:BIIB) traded up 0.24% during mid-day trading on Tuesday, hitting $329.81. 366,418 shares of the company were exchanged. The firm has a 50 day moving average price of $312.85 and a 200 day moving average price of $281.74. The stock has a market cap of $69.73 billion, a price-to-earnings ratio of 21.64 and a beta of 0.77. Biogen Inc. has a 12 month low of $244.28 and a 12 month high of $332.61.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, topping the consensus estimate of $4.36 by $0.68. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. Biogen’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the company posted $5.21 EPS. Analysts anticipate that Biogen Inc. will post $21.53 EPS for the current fiscal year.

BIIB has been the subject of several analyst reports. Vetr cut shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 target price for the company. in a research note on Tuesday, August 29th. ValuEngine upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Cowen and Company reiterated an “outperform” rating and issued a $271.00 target price on shares of Biogen in a research note on Monday, July 3rd. Royal Bank Of Canada reiterated a “hold” rating and issued a $315.00 target price on shares of Biogen in a research note on Thursday, October 5th. Finally, William Blair reiterated an “outperform” rating on shares of Biogen in a research note on Monday, June 26th. Thirteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $330.66.

COPYRIGHT VIOLATION NOTICE: “Fairfield Bush & CO. Maintains Holdings in Biogen Inc. (BIIB)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/10/10/fairfield-bush-co-maintains-holdings-in-biogen-inc-biib.html.

In other Biogen news, EVP Susan H. Alexander sold 4,974 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Susan H. Alexander sold 7,758 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total value of $2,211,030.00. Following the completion of the transaction, the executive vice president now directly owns 27,232 shares in the company, valued at $7,761,120. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

What are top analysts saying about Biogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biogen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit